As the Medicines and Healthcare products Regulatory Agency (MHRA) enters a new era under new leadership, rebuilding UK excellence in medicines regulation will be central in securing UK life science competitiveness.
Excellence in medicines regulation is a pre-condition for any country seeking to be a global leader in life science research and development.
Reaffirming the MHRA’s status as a world-class regulator will be a key objective for its incoming new Chair, Professor Anthony Harnden, and its new Chief Executive, when appointed. [2]
In a new report ‘Enhancing the role of UK medicine regulation’ [1] the Association of the British Pharmaceutical Industry (ABPI) explores the crucial role of regulatory excellence in driving innovation and early access, supporting patient trust, and attracting investment into the UK.
Drawing on evidence from the life sciences community, the report sets out key recommendations in the following areas to rebuild the UK’s world-class reputation in regulatory science, medicines’ development and licensing:
- Enhancing communications, transparency, and accountability.
- Improving resourcing and expertise to support its regulatory functions.
- Strengthening the regulatory framework with flexible licensing routes, expedited clinical trial approvals and horizon scanning capabilities.
Read the Full Story Here: https://www.abpi.org.uk/media/news/2024/december/regulatory-renewal-needed-for-uk-life-sciences-ambitions/